Citigroup
VTVT icon

Citigroup’s vTv Therapeutics VTVT Stock Holding History

Citigroup’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-244
Closed -$9.76K – 6436
2025
Q4 		$9.76K Buy
244
+243
+24,300% +$6.76K ﹤0.01% 5060
2025
Q3 		$23 Buy
+1
New +$18 ﹤0.01% 5898
2021
Q2 		– Sell
-20
Closed -$2K – 6426
2021
Q1 		$2K Sell
20
-26
-57% -$2.55K ﹤0.01% 6063
2020
Q4 		$3K Buy
46
+33
+254% +$2.53K ﹤0.01% 7214
2020
Q3 		$1K Sell
13
-17
-57% -$1.49K ﹤0.01% 7391
2020
Q2 		$3K Buy
+30
New +$2.96K ﹤0.01% 7367
2018
Q3 		– Sell
-96
Closed -$6K – 7885
2018
Q2 		$6K Buy
+96
New +$7.09K ﹤0.01% 7313
2018
Q1 		– Sell
-18
Closed -$4K – 7685
2017
Q4 		$4K Buy
+18
New +$4.04K ﹤0.01% 7291
2017
Q3 		– Sell
-2
Closed – – 7456
2017
Q2 		$0 Sell
2
-2
-50% -$417 ﹤0.01% 7500
2017
Q1 		$1K Sell
4
-39
-91% -$8.89K ﹤0.01% 7112
2016
Q4 		$8K Buy
+43
New +$9.88K ﹤0.01% 6814
2016
Q2 		– Sell
-107
Closed -$22K – 7473
2016
Q1 		$22K Buy
107
+97
+970% +$24.1K ﹤0.01% 6511
2015
Q4 		$3K Buy
+10
New +$2.81K ﹤0.01% 7209
2015
Q3 		– Hold
0
– – – 7740

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citigroup's VTVT Position: Q1 2026 in Review

Citigroup sold out of vTv Therapeutics (VTVT) in Q1 2026, closing a stake of 244 shares — an estimated $9.76K sold.

Citigroup first reported a position in VTVT in Q4 2015 and held it in 13 quarters. The position peaked at $22K in Q1 2016. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.

  • Citigroup reported no remaining vTv Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 244 vTv Therapeutics shares in Q1 2026, an estimated $9.76K.
  • Citigroup first reported a position in vTv Therapeutics in Q4 2015 and held it in 13 quarters.
  • Citigroup's vTv Therapeutics position peaked at $22K in Q1 2016.
  • 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.